<p>Pharma major Glenmark Pharmaceuticals Limited on Thursday said it has launched a fixed-dose combination for the treatment of diabetes for patients with comorbidities.</p>.<p>The Mumbai-based drug maker said it has become the first company to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed-dose combination for the treatment of adult patients with type 2 diabetes.</p>.<p>Marketed under the brand name Zita D, it contains Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg), and must be taken once daily under prescription to improve glycemic control and prevent complications in adult patients with type 2 diabetes, especially the ones with comorbidities, Glenmark Pharma said in a statement.</p>.<p>"Diabetes is growing in India at an alarming rate, and eight out of every ten diabetic patients suffer from comorbidities," Glenmark Pharmaceuticals EVP & Business Head India Formulations Alok Malik said.</p>.<p>The new drug is well researched and affordable fixed-dose combination, which will significantly improve glycemic control in adult patients, he added.</p>
<p>Pharma major Glenmark Pharmaceuticals Limited on Thursday said it has launched a fixed-dose combination for the treatment of diabetes for patients with comorbidities.</p>.<p>The Mumbai-based drug maker said it has become the first company to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed-dose combination for the treatment of adult patients with type 2 diabetes.</p>.<p>Marketed under the brand name Zita D, it contains Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg), and must be taken once daily under prescription to improve glycemic control and prevent complications in adult patients with type 2 diabetes, especially the ones with comorbidities, Glenmark Pharma said in a statement.</p>.<p>"Diabetes is growing in India at an alarming rate, and eight out of every ten diabetic patients suffer from comorbidities," Glenmark Pharmaceuticals EVP & Business Head India Formulations Alok Malik said.</p>.<p>The new drug is well researched and affordable fixed-dose combination, which will significantly improve glycemic control in adult patients, he added.</p>